$7.17
0.04[0.56%]
At close: Apr 25
$7.17
0[0.00%]
PreMarket: 6:23PM EDT
Fulcrum Therapeutics
(NASDAQ:FULC)Fulcrum Therapeutics Stock (NASDAQ:FULC), Analyst Ratings, Price Targets, Predictions
Fulcrum Therapeutics Inc has a consensus price target of $13.9, established from looking at the 38 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, HC Wainwright & Co., and Piper Sandler on March 13, 2024, February 28, 2024, and February 28, 2024. With an average price target of $15.33 between RBC Capital, HC Wainwright & Co., and Piper Sandler, there's an implied 113.85% upside for Fulcrum Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Piper Sandler
Goldman Sachs
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Fulcrum Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/13/2024 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 95.26% | RBC Capital | Gregory Renza | → $14 | Initiates | → Outperform | Get Alert |
| 02/28/2024 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 137.1% | HC Wainwright & Co. | Andrew Fein | $14 → $17 | Maintains | Buy | Get Alert |
| 02/28/2024 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 109.21% | Piper Sandler | Edward Tenthoff | $13 → $15 | Maintains | Overweight | Get Alert |
| 01/26/2024 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -16.32% | Goldman Sachs | Madhu Kumar | $5 → $6 | Maintains | Neutral | Get Alert |
| 01/25/2024 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -16.32% | Goldman Sachs | Madhu Kumar | $5 → $6 | Maintains | Neutral | Get Alert |
| 09/25/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -30.26% | Goldman Sachs | Madhu Kumar | → $5 | Initiates | → Neutral | Get Alert |
| 08/23/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 95.26% | HC Wainwright & Co. | Andrew Fein | $5 → $14 | Upgrade | Neutral → Buy | Get Alert |
| 08/22/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 123.15% | Oppenheimer | Matthew Biegler | → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 08/22/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 53.42% | Stifel | Dae Gon Ha | → $11 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -30.26% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 05/16/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 123.15% | Oppenheimer | Matthew Biegler | $20 → $16 | Maintains | Outperform | Get Alert |
| 05/16/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -30.26% | HC Wainwright & Co. | Andrew Fein | $6 → $5 | Maintains | Neutral | Get Alert |
| 05/05/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -58.16% | Goldman Sachs | Madhu Kumar | $9 → $3 | Maintains | Neutral | Get Alert |
| 05/04/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -58.16% | Goldman Sachs | Madhu Kumar | $9 → $3 | Downgrade | Buy → Neutral | Get Alert |
| 03/13/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 25.52% | Goldman Sachs | Madhu Kumar | $17 → $9 | Maintains | Buy | Get Alert |
| 03/10/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -2.37% | Morgan Stanley | Matthew Korn | $8 → $7 | Maintains | Equal-Weight | Get Alert |
| 03/10/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | -16.32% | HC Wainwright & Co. | Andrew Fein | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 03/10/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 11.58% | Credit Suisse | Judah Frommer | $11 → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 02/28/2023 | FULC | Buy Now | Fulcrum Therapeutics | $7.17 | 178.94% | HC Wainwright & Co. | Andrew Fein | → $20 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Fulcrum Therapeutics (FULC)?
The latest price target for Fulcrum Therapeutics (NASDAQ: FULC) was reported by RBC Capital on March 13, 2024. The analyst firm set a price target for $14.00 expecting FULC to rise to within 12 months (a possible 95.26% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fulcrum Therapeutics (FULC)?
The latest analyst rating for Fulcrum Therapeutics (NASDAQ: FULC) was provided by RBC Capital, and Fulcrum Therapeutics initiated their outperform rating.
When was the last upgrade for Fulcrum Therapeutics (FULC)?
The last upgrade for Fulcrum Therapeutics Inc happened on August 23, 2023 when HC Wainwright & Co. raised their price target to $14. HC Wainwright & Co. previously had a neutral for Fulcrum Therapeutics Inc.
When was the last downgrade for Fulcrum Therapeutics (FULC)?
The last downgrade for Fulcrum Therapeutics Inc happened on May 4, 2023 when Goldman Sachs changed their price target from $9 to $3 for Fulcrum Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fulcrum Therapeutics (FULC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on March 13, 2024 so you should expect the next rating to be made available sometime around March 13, 2025.
Is the Analyst Rating Fulcrum Therapeutics (FULC) correct?
While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a initiated with a price target of $0.00 to $14.00. The current price Fulcrum Therapeutics (FULC) is trading at is $7.17, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.